The DOI matches its Crossref record; 205 of the 205 references it cites were found in a registry or an index.
VHL, the story of a tumour suppressor gene
Open accessAbstract
The identification in 1993 of inherited mutations in the von Hippel–Lindau (VHL) gene in families with VHL disease was a seminal finding. This and subsequent discoveries have given the VHLtumour suppressor gene a central role in our understanding of the mechanisms of cellular oxygen sensing and in the pathobiology of clear-cell renal cell carcinoma. Since the Von Hippel–Lindau (VHL) disease tumour suppressor gene VHL was identified in 1993 as the genetic basis for a rare disorder, it has proved to be of wide medical and scientific interest. VHL tumour suppressor protein (pVHL) plays a key part in cellular oxygen sensing by targeting hypoxia-inducible factors for ubiquitylation and proteasomal degradation. Early inactivation of VHL is commonly seen in clear-cell renal cell carcinoma (ccRCC), and insights gained from the functional analysis of pVHL have provided the foundation for the routine treatment of advanced-stage ccRCC with novel targeted therapies. However, recent sequencing studies have identified additional driver genes that are involved in the pathogenesis of ccRCC. As our understanding of the importance of VHL matures, it is timely to review progress from its initial description to current knowledge of VHL biology, as well as future prospects for novel medical treatments for VHL disease and ccRCC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization
Lee, K., Zhang, H., Qian, D. Z., Rey, S., Liu, J. O., & Semenza, G. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0909353106 · Cited by 451
RetractedIntratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Mutation and cancer: statistical study of retinoblastoma
Knudson, A. G. (1971) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.68.4.820 · Cited by 7,612
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Self-citationTargeting Hypoxia-Inducible Factors for the Treatment of Anemia in Chronic Kidney Disease Patients
Locatelli, F., Fishbane, S., Block, G. A., & Macdougall, I. C. (2017) · American Journal of Nephrology · doi:10.1159/000455166 · Cited by 4,813
HIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Comprehensive molecular characterization of clear cell renal cell carcinoma
The Cancer Genome Atlas Research Network (2013) · Nature · doi:10.1038/nature12222 · Cited by 3,485
Identification of the von Hippel-Lindau Disease Tumor Suppressor Gene
Latif, F., Tory, K., Gnarra, J., Yao, M., Duh, F.-M., Orcutt, M. L., Stackhouse, T., Kuzmin, I., Modi, W., Geil, L., et al. (1993) · Science · doi:10.1126/science.8493574 · Cited by 2,973
Self-citationA conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Mutations of the VHL tumour suppressor gene in renal carcinoma
Gnarra, J. R., Tory, K., Weng, Y., Schmidt, L., Wei, M. H., Li, H., Latif, F., Liu, S., Chen, F., Duh, F.-M., et al. (1994) · Nature Genetics · doi:10.1038/ng0594-85 · Cited by 1,730
HIF1α and HIF2α: sibling rivalry in hypoxic tumour growth and progression
Keith, B., Johnson, R. S., & Simon, M. C. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3183 · Cited by 1,693
Ohh, M., Park, C. W., Ivan, M., Hoffman, M. A., Kim, T.-Y., Huang, L. E., Pavletich, N., Chau, V., & Kaelin, W. G. (2000) · Nature Cell Biology · doi:10.1038/35017054 · Cited by 1,577
Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy
Semenza, G. L. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.01.005 · Cited by 1,514
Differential Roles of Hypoxia-Inducible Factor 1α (HIF-1α) and HIF-2α in Hypoxic Gene Regulation
Hu, C.-J., Wang, L.-Y., Chodosh, L. A., Keith, B., & Simon, M. C. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.24.9361-9374.2003 · Cited by 1,386
The Concept of Synthetic Lethality in the Context of Anticancer Therapy
Kaelin, W. G. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1691 · Cited by 1,379
Germ-Line Mutations in Nonsyndromic Pheochromocytoma
Neumann, H. P. H., Bausch, B., McWhinney, S. R., Bender, B. U., Gimm, O., Franke, G., Schipper, J., Klisch, J., Altehoefer, C., Zerres, K., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020152 · Cited by 1,367
Integrated molecular analysis of clear-cell renal cell carcinoma
Sato, Y., Yoshizato, T., Shiraishi, Y., Maekawa, S., Okuno, Y., Kamura, T., Shimamura, T., Sato-Otsubo, A., Nagae, G., Suzuki, H., et al. (2013) · Nature Genetics · doi:10.1038/ng.2699 · Cited by 1,221
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes
Dalgliesh, G. L., Furge, K., Greenman, C., Chen, L., Bignell, G., Butler, A., Davies, H., Edkins, S., Hardy, C., Latimer, C., et al. (2010) · Nature · doi:10.1038/nature08672 · Cited by 1,173
Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma
Varela, I., Tarpey, P., Raine, K., Huang, D., Ong, C. K., Stephens, P., Davies, H., Jones, D., Lin, M.-L., Teague, J., et al. (2011) · Nature · doi:10.1038/nature09639 · Cited by 1,123
Cockman, M. E., Masson, N., Mole, D. R., Jaakkola, P., Chang, G.-W., Clifford, S. C., Maher, E. R., Pugh, C. W., Ratcliffe, P. J., & Maxwell, P. H. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.m002740200 · Cited by 1,050
Self-citationOxygen Sensing, Homeostasis, and Disease
Semenza, G. L. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011165 · Cited by 993
BAP1 loss defines a new class of renal cell carcinoma
Peña-Llopis, S., Vega-Rubín-de-Celis, S., Liao, A., Leng, N., Pavía-Jiménez, A., Wang, S., Yamasaki, T., Zhrebker, L., Sivanand, S., Spence, P., et al. (2012) · Nature Genetics · doi:10.1038/ng.2323 · Cited by 959
Raval, R. R., Lau, K. W., Tran, M. G. B., Sowter, H. M., Mandriota, S. J., Li, J.-L., Pugh, C. W., Maxwell, P. H., Harris, A. L., & Ratcliffe, P. J. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5675-5686.2005 · Cited by 940
Tanimoto, K., Makino, Y., Pereira, T., & Poellinger, L. (2000) · The EMBO Journal · doi:10.1093/emboj/19.16.4298 · Cited by 928
The Catalogue of Somatic Mutations in Cancer (COSMIC)
Forbes, S. A., Bhamra, G., Bamford, S., Dawson, E., Kok, C., Clements, J., Menzies, A., Teague, J. W., Futreal, P. A., & Stratton, M. R. (2008) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg1011s57 · Cited by 904
Negative regulation of hypoxia-inducible genes by the von Hippel-Lindau protein.
Iliopoulos, O., Levy, A. P., Jiang, C., Kaelin, W. G., & Goldberg, M. A. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10595 · Cited by 892
Chemokine receptor CXCR4 downregulated by von Hippel–Lindau tumour suppressor pVHL
Staller, P., Sulitkova, J., Lisztwan, J., Moch, H., Oakeley, E. J., & Krek, W. (2003) · Nature · doi:10.1038/nature01874 · Cited by 870
Structure of the VHL-ElonginC-ElonginB Complex: Implications for VHL Tumor Suppressor Function
Stebbins, C. E., Kaelin, W. G., & Pavletich, N. P. (1999) · Science · doi:10.1126/science.284.5413.455 · Cited by 860
HIF-1α binding to VHL is regulated by stimulus-sensitive proline hydroxylation
Yu, F., White, S. B., Zhao, Q., & Lee, F. S. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.181341498 · Cited by 796
Somatic mutations of the histone H3K27 demethylase gene UTX in human cancer
van Haaften, G., Dalgliesh, G. L., Davies, H., Chen, L., Bignell, G., Greenman, C., Edkins, S., Hardy, C., O'Meara, S., Teague, J., et al. (2009) · Nature Genetics · doi:10.1038/ng.349 · Cited by 784
Rbx1, a Component of the VHL Tumor Suppressor Complex and SCF Ubiquitin Ligase
Kamura, T., Koepp, D. M., Conrad, M. N., Skowyra, D., Moreland, R. J., Iliopoulos, O., Lane, W. S., Kaelin, W. G., Elledge, S. J., Conaway, R. C., et al. (1999) · Science · doi:10.1126/science.284.5414.657 · Cited by 781
Structure of an HIF-1α-pVHL Complex: Hydroxyproline Recognition in Signaling
Min, J.-H., Yang, H., Ivan, M., Gertler, F., Kaelin, W. G., & Pavletich, N. P. (2002) · Science · doi:10.1126/science.1073440 · Cited by 765
Inhibition of HIF is necessary for tumor suppression by the von Hippel-Lindau protein
Kondo, K., Klco, J., Nakamura, E., Lechpammer, M., & Kaelin, W. G. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00043-0 · Cited by 761
Structural basis for the recognition of hydroxyproline in HIF-1α by pVHL
Hon, W.-C., Wilson, M. I., Harlos, K., Claridge, T. D. W., Schofield, C. J., Pugh, C. W., Maxwell, P. H., Ratcliffe, P. J., Stuart, D. I., & Jones, E. Y. (2002) · Nature · doi:10.1038/nature00767 · Cited by 751
von Hippel–Lindau disease: A clinical and scientific review
Maher, E. R., Neumann, H. P., & Richard, S. (2011) · European Journal of Human Genetics · doi:10.1038/ejhg.2010.175 · Cited by 729
Self-citationHigh-resolution genome-wide mapping of HIF-binding sites by ChIP-seq
Schödel, J., Oikonomopoulos, S., Ragoussis, J., Pugh, C. W., Ratcliffe, P. J., & Mole, D. R. (2011) · Blood · doi:10.1182/blood-2010-10-314427 · Cited by 724
Tumour suppression by the human von Hippel-Lindau gene product
Iliopoulos, O., Kibel, A., Gray, S., & Kaelin, W. G. (1995) · Nature Medicine · doi:10.1038/nm0895-822 · Cited by 703
Binding of the von Hippel-Lindau Tumor Suppressor Protein to Elongin B and C
Kibel, A., Iliopoulos, O., DeCaprio, J. A., & Kaelin, W. G. (1995) · Science · doi:10.1126/science.7660130 · Cited by 671
Loss of alleles of loci on the short arm of chromosome 3 in renal cell carcinoma
Zbar, B., Brauch, H., Talmadge, C., & Linehan, M. (1987) · Nature · doi:10.1038/327721a0 · Cited by 638
Inhibition of HIF2α Is Sufficient to Suppress pVHL-Defective Tumor Growth
Kondo, K., Kim, W. Y., Lechpammer, M., & Kaelin, W. G. (2003) · PLoS Biology · doi:10.1371/journal.pbio.0000083 · Cited by 611
Hypoxia-inducible factor-2 (HIF-2) regulates hepatic erythropoietin in vivo
Rankin, E. B., Biju, M. P., Liu, Q., Unger, T. L., Rha, J., Johnson, R. S., Simon, M. C., Keith, B., & Haase, V. H. (2007) · Journal of Clinical Investigation · doi:10.1172/jci30117 · Cited by 596
Inhibition of Transcription Elongation by the VHL Tumor Suppressor Protein
Duan, D. R., Pause, A., Burgess, W. H., Aso, T., Chen, D. Y. T., Garrett, K. P., Conaway, R. C., Conaway, J. W., Linehan, W. M., & Klausner, R. D. (1995) · Science · doi:10.1126/science.7660122 · Cited by 568
Targeting GLUT1 and the Warburg Effect in Renal Cell Carcinoma by Chemical Synthetic Lethality
Chan, D. A., Sutphin, P. D., Nguyen, P., Turcotte, S., Lai, E. W., Banh, A., Reynolds, G. E., Chi, J.-T., Wu, J., Solow-Cordero, D. E., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002394 · Cited by 557
Chen, F., Kishida, T., Yao, M., Hustad, T., Glavac, D., Dean, M., Gnarra, J. R., Orcutt, M. L., Duh, F. M., Glenn, G., et al. (1995) · Human Mutation · doi:10.1002/humu.1380050109 · Cited by 556
Gnarra, J. R., Zhou, S., Merrill, M. J., Wagner, J. R., Krumm, A., Papavassiliou, E., Oldfield, E. H., Klausner, R. D., & Linehan, W. M. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.20.10589 · Cited by 531
Lee, S., Nakamura, E., Yang, H., Wei, W., Linggi, M. S., Sajan, M. P., Farese, R. V., Freeman, R. S., Carter, B. D., Kaelin, W. G., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.015 · Cited by 527
Disruption of oxygen homeostasis underlies congenital Chuvash polycythemia
Ang, S. O., Chen, H., Hirota, K., Gordeuk, V. R., Jelinek, J., Guan, Y., Liu, E., Sergueeva, A. I., Miasnikova, G. Y., Mole, D., et al. (2002) · Nature Genetics · doi:10.1038/ng1019 · Cited by 510
Iwai, K., Yamanaka, K., Kamura, T., Minato, N., Conaway, R. C., Conaway, J. W., Klausner, R. D., & Pause, A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.22.12436 · Cited by 508
Pause, A., Lee, S., Worrell, R. A., Chen, D. Y. T., Burgess, W. H., Linehan, W. M., & Klausner, R. D. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.6.2156 · Cited by 493
HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma
Gordan, J. D., Lal, P., Dondeti, V. R., Letrero, R., Parekh, K. N., Oquendo, C. E., Greenberg, R. A., Flaherty, K. T., Rathmell, W. K., Keith, B., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.10.016 · Cited by 493
HIF activation identifies early lesions in VHL kidneys
Mandriota, S. J., Turner, K. J., Davies, D. R., Murray, P. G., Morgan, N. V., Sowter, H. M., Wykoff, C. C., Maher, E. R., Harris, A. L., Ratcliffe, P. J., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00071-5 · Cited by 483
Self-citationOhh, M., Yauch, R. L., Lonergan, K. M., Whaley, J. M., Stemmer-Rachamimov, A. O., Louis, D. N., Gavin, B. J., Kley, N., Kaelin, W. G., & Iliopoulos, O. (1998) · Molecular Cell · doi:10.1016/s1097-2765(00)80096-9 · Cited by 477
Acute postnatal ablation of Hif-2 α results in anemia
Gruber, M., Hu, C.-J., Johnson, R. S., Brown, E. J., Keith, B., & Simon, M. C. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0608382104 · Cited by 457
Maranchie, J. K., Vasselli, J. R., Riss, J., Bonifacino, J. S., Linehan, W. M., & Klausner, R. D. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00044-2 · Cited by 432
Frydman, J., Nimmesgern, E., Erdjument-Bromage, H., Wall, J. S., Tempst, P., & Hartl, F. U. (1992) · The EMBO Journal · doi:10.1002/j.1460-2075.1992.tb05582.x · Cited by 413
Genetic and Functional Studies Implicate HIF1 α as a 14q Kidney Cancer Suppressor Gene
Shen, C., Beroukhim, R., Schumacher, S. E., Zhou, J., Chang, M., Signoretti, S., & Kaelin, W. G. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0098 · Cited by 413
Xia, X., Lemieux, M. E., Li, W., Carroll, J. S., Brown, M., Liu, X. S., & Kung, A. L. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0810067106 · Cited by 410
Hoffman, M. A. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1019 · Cited by 382
Lonergan, K. M., Iliopoulos, O., Ohh, M., Kamura, T., Conaway, R. C., Conaway, J. W., & Kaelin, W. G. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.2.732 · Cited by 381
Lisztwan, J., Imbert, G., Wirbelauer, C., Gstaiger, M., & Krek, W. (1999) · Genes & Development · doi:10.1101/gad.13.14.1822 · Cited by 379
Clifford, S. C. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.10.1029 · Cited by 373
Foster, K., Prowse, A., van den Berg, A., Fleming, S., Hulsbeek, M. M. F., Crossey, P. A., Richards, F. M., Cairns, P., Affara, N. A., Ferguson-Smith, M. A., et al. (1994) · Human Molecular Genetics · doi:10.1093/hmg/3.12.2169 · Cited by 373
Self-citationRankin, E. B., Tomaszewski, J. E., & Haase, V. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3241 · Cited by 363
Hakimi, A. A., Ostrovnaya, I., Reva, B., Schultz, N., Chen, Y.-B., Gonen, M., Liu, H., Takeda, S., Voss, M. H., Tickoo, S. K., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-3886 · Cited by 357
Carroll, V. A., & Ashcroft, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2519 · Cited by 352
高橋, 敦. (1994) · Medical Entomology and Zoology · doi:10.11501/3101325 · Cited by 352
Mukhopadhyay, D., Knebelmann, B., Cohen, H. T., Ananth, S., & Sukhatme, V. P. (1997) · Molecular and Cellular Biology · doi:10.1128/mcb.17.9.5629 · Cited by 341
Beyer, S., Kristensen, M. M., Jensen, K. S., Johansen, J. V., & Staller, P. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m804578200 · Cited by 340
Clustering of features of von Hippel-Lindau syndrome: evidence for a complex genetic locus
Neumann, H. P. H., & Wiestler, O. D. (1991) · The Lancet · doi:10.1016/0140-6736(91)91705-y · Cited by 340
Regulation of microtubule stability by the von Hippel-Lindau tumour suppressor protein pVHL
Hergovich, A., Lisztwan, J., Barry, R., Ballschmieter, P., & Krek, W. (2003) · Nature Cell Biology · doi:10.1038/ncb899 · Cited by 339
Hypoxia-inducible factor 2 regulates hepatic lipid metabolism
Rankin, E. B., Rha, J., Selak, M. A., Unger, T. L., Keith, B., Liu, Q., & Haase, V. H. (2009) · Molecular and Cellular Biology · doi:10.1128/mcb.00200-09 · Cited by 338
Guo, G., Gui, Y., Gao, S., Tang, A., Hu, X., Huang, Y., Jia, W., Li, Z., He, M., Sun, L., et al. (2012) · Nature Genetics · doi:10.1038/ng.1014 · Cited by 326
Wizigmann-Voos, S., Breier, G., Risau, W., & Plate, K. H. (1995) · PubMed · Cited by 326
Allosteric inhibition of hypoxia inducible factor-2 with small molecules
Scheuermann, T. H., Li, Q., Ma, H.-W., Key, J., Zhang, L., Chen, R., Garcia, J. A., Naidoo, J., Longgood, J., Frantz, D. E., et al. (2013) · Nature Chemical Biology · doi:10.1038/nchembio.1185 · Cited by 315
Genetic analysis of von Hippel-Lindau disease
Nordstrom-O'Brien, M., van der Luijt, R. B., van Rooijen, E., van den Ouweland, A. M., Majoor-Krakauer, D. F., Lolkema, M. P., van Brussel, A., Voest, E. E., & Giles, R. H. (2010) · Human Mutation · doi:10.1002/humu.21219 · Cited by 311
Molecular Genetics of Clear-Cell Renal Cell Carcinoma
Brugarolas, J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2003 · Cited by 306
Artificial ligand binding within the HIF2α PAS-B domain of the HIF2 transcription factor
Scheuermann, T. H., Tomchick, D. R., Machius, M., Guo, Y., Bruick, R. K., & Gardner, K. H. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808092106 · Cited by 301
Regulation of Jumonji-domain-containing histone demethylases by hypoxia-inducible factor (HIF)-1α
Pollard, P. J., Loenarz, C., Mole, D. R., McDonough, M. A., Gleadle, J. M., Schofield, C. J., & Ratcliffe, P. J. (2008) · Biochemical Journal · doi:10.1042/bj20081238 · Cited by 295
Über eine sehr seltene Erkrankung der Netzhaut: Klinische Beobachtungen
Hippel, E. (1904) · Albrecht von Græfe's Archiv für Ophthalmologie · doi:10.1007/bf01994821 · Cited by 293
Takahashi, A., Sasaki, H., Kim, S. J., Tobisu, K.-I., Kakizoe, T., Tsukamoto, T., Kumamoto, Y., Sugimura, T., & Terada, M. (1994) · PubMed · Cited by 275
Interplay between HDAC3 and WDR5 Is Essential for Hypoxia-Induced Epithelial-Mesenchymal Transition
Wu, M.-Z., Tsai, Y.-P., Yang, M.-H., Huang, C.-H., Chang, S.-Y., Chang, C.-C., Teng, S.-C., & Wu, K.-J. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.07.012 · Cited by 273
Clifford, S. C., Prowse, A. H., Affara, N. A., Buys, C. H. C. M., & Maher, E. R. (1998) · Genes, Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199807)22:3<200::aid-gcc5>3.0.co;2-# · Cited by 270
Self-citationIliopoulos, O., Ohh, M., & Kaelin, W. G. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.20.11661 · Cited by 260
Zagzag, D., Krishnamachary, B., Yee, H., Okuyama, H., Chiriboga, L., Ali, M. A., Melamed, J., & Semenza, G. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4406 · Cited by 260
Folding and Quality Control of the VHL Tumor Suppressor Proceed through Distinct Chaperone Pathways
McClellan, A. J., Scott, M. D., & Frydman, J. (2005) · Cell · doi:10.1016/j.cell.2005.03.024 · Cited by 259
A Molecule Targeting VHL-Deficient Renal Cell Carcinoma that Induces Autophagy
Turcotte, S., Chan, D. A., Sutphin, P. D., Hay, M. P., Denny, W. A., & Giaccia, A. J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.004 · Cited by 251
Genotype-phenotype correlations in von Hippel-Lindau disease
Ong, K. R., Woodward, E. R., Killick, P., Lim, C., Macdonald, F., & Maher, E. R. (2007) · Human Mutation · doi:10.1002/humu.20385 · Cited by 250
Self-citationVHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail
Evans, A. J., Russell, R. C., Roche, O., Burry, T. N., Fish, J. E., Chow, V. W. K., Kim, W. Y., Saravanan, A., Maynard, M. A., Gervais, M. L., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00892-06 · Cited by 248
Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL−/− tumors
Zimmer, M., Doucette, D., Siddiqui, N., & Iliopoulos, O. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.89.2.2 · Cited by 244
Duns, G., van den Berg, E., van Duivenbode, I., Osinga, J., Hollema, H., Hofstra, R. M. W., & Kok, K. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0120 · Cited by 239
VHL loss actuates a HIF-independent senescence programme mediated by Rb and p400
Young, A. P., Schlisio, S., Minamishima, Y. A., Zhang, Q., Li, L., Grisanzio, C., Signoretti, S., & Kaelin, W. G. (2008) · Nature Cell Biology · doi:10.1038/ncb1699 · Cited by 239
Formation of the VHL–Elongin BC Tumor Suppressor Complex Is Mediated by the Chaperonin TRiC
Feldman, D. E., Thulasiraman, V., Ferreyra, R. G., & Frydman, J. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80233-6 · Cited by 238
The von Hippel–Lindau tumor suppressor gene is required for cell cycle exit upon serum withdrawal
Pause, A., Lee, S., Lonergan, K. M., & Klausner, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.3.993 · Cited by 238
p53 Stabilization and Transactivation by a von Hippel-Lindau Protein
Roe, J.-S., Kim, H., Lee, S.-M., Kim, S.-T., Cho, E.-J., & Youn, H.-D. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.04.006 · Cited by 237
Failure to prolyl hydroxylate hypoxia‐inducible factor α phenocopies VHL inactivation in vivo
Kim, W. Y., Safran, M., Buckley, M. R., Ebert, B. L., Glickman, J., Bosenberg, M., Regan, M., & Kaelin, W. G. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601300 · Cited by 235
HIF-2α regulates murine hematopoietic development in an erythropoietin-dependent manner
Scortegagna, M., Ding, K., Zhang, Q., Oktay, Y., Bennett, M. J., Bennett, M., Shelton, J. M., Richardson, J. A., Moe, O., & Garcia, J. A. (2005) · Blood · doi:10.1182/blood-2004-05-1695 · Cited by 233
Whaley, J. M., Naglich, J. G., Gelbert, L. M., Hsia, Y. E., Lamiell, J. M., Green, J. S., Collins, D. L., Neumann, H. P. H., Laidlaw, J., & Li, F. P. (1994) · PubMed Central · Cited by 232
Kuznetsova, A. V., Meller, J., Schnell, P. O., Nash, J. A., Ignacak, M. L., Sanchez, Y., Conaway, J. W., Conaway, R. C., & Czyzyk-Krzeska, M. F. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0436037100 · Cited by 232
Hakimi, A. A., Chen, Y.-B., Wren, J., Gonen, M., Abdel-Wahab, O., Heguy, A., Liu, H., Takeda, S., Tickoo, S. K., Reuter, V. E., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.09.005 · Cited by 231
Schoenfeld, A., Davidowitz, E. J., & Burk, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.15.8817 · Cited by 230
HIF2α Acts as an mTORC1 Activator through the Amino Acid Carrier SLC7A5
Elorza, A., Soro-Arnáiz, I., Meléndez-Rodríguez, F., Rodríguez-Vaello, V., Marsboom, G., de Cárcer, G., Acosta-Iborra, B., Albacete-Albacete, L., Ordóñez, A., Serrano-Oviedo, L., et al. (2012) · Molecular Cell · doi:10.1016/j.molcel.2012.09.017 · Cited by 205
Choueiri, T. K., Vaziri, S. A. J., Jaeger, E., Elson, P., Wood, L., Bhalla, I. P., Small, E. J., Weinberg, V., Sein, N., Simko, J., et al. (2008) · Journal of Urology · doi:10.1016/j.juro.2008.05.015 · Cited by 202
HIF-1 antagonizes p53-mediated apoptosis through a secreted neuronal tyrosinase
Sendoel, A., Kohler, I., Fellmann, C., Lowe, S. W., & Hengartner, M. O. (2010) · Nature · doi:10.1038/nature09141 · Cited by 192
Zimmer, M., Ebert, B. L., Neil, C., Brenner, K., Papaioannou, I., Melas, A., Tolliday, N., Lamb, J., Pantopoulos, K., Golub, T., et al. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.12.004 · Cited by 191
Gunaratnam, L., Morley, M., Franovic, A., de Paulsen, N., Mekhail, K., Parolin, D. A. E., Nakamura, E., Lorimer, I. A. J., & Lee, S. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m305502200 · Cited by 188
Petrella, B. L., Lohi, J., & Brinckerhoff, C. E. (2005) · Oncogene · doi:10.1038/sj.onc.1208305 · Cited by 188
Stickle, N. H., Chung, J., Klco, J. M., Hill, R. P., Kaelin, W. G., & Ohh, M. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.8.3251-3261.2004 · Cited by 185
pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF-κB Agonist Card9 by CK2
Yang, H., Minamishima, Y. A., Yan, Q., Schlisio, S., Ebert, B. L., Zhang, X., Zhang, L., Kim, W. Y., Olumi, A. F., & Kaelin, W. G. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.09.010 · Cited by 179
Cho, D., Signoretti, S., Dabora, S., Regan, M., Seeley, A., Mariotti, M., Youmans, A., Polivy, A., Mandato, L., McDermott, D., et al. (2007) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2007.n.020 · Cited by 178
Maher, E. R., Yates, J. R., & Ferguson-Smith, M. A. (1990) · Journal of Medical Genetics · doi:10.1136/jmg.27.5.311 · Cited by 177
Self-citationZUR FRAGE DER ANGIOMATOSIS RETINæ UND IHRER HIRNKOMPLIKATIONEN
LINDAU, A. (1926) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.1926.tb07786.x · Cited by 175
The von Hippel-Lindau tumor suppressor protein controls ciliogenesis by orienting microtubule growth
Schermer, B., Ghenoiu, C., Bartram, M., Müller, R. U., Kotsis, F., Höhne, M., Kühn, W., Rapka, M., Nitschke, R., Zentgraf, H., et al. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200605092 · Cited by 174
Young, A. C., Craven, R. A., Cohen, D., Taylor, C., Booth, C., Harnden, P., Cairns, D. A., Astuti, D., Gregory, W., Maher, E. R., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-2131 · Cited by 173
Self-citationPeña, C., Lathia, C., Shan, M., Escudier, B., & Bukowski, R. M. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3343 · Cited by 173
Eng, C., Crossey, P. A., Mulligan, L. M., Healey, C. S., Houghton, C., Prowse, A., Chew, S. L., Dahia, P. L., O'Riordan, J. L., & Toledo, S. P. (1995) · Journal of Medical Genetics · doi:10.1136/jmg.32.12.934 · Cited by 172
Transforming growth factor alpha is a target for the von Hippel-Lindau tumor suppressor.
Knebelmann, B., Karumanchi, S. A., Cohen, H. T., & Sukhatme, V. P. (1998) · PubMed · Cited by 170
Niu, X., Zhang, T., Liao, L., Zhou, L., Lindner, D. J., Zhou, M., Rini, B. I., Yan, Q., & Yang, H. (2011) · Oncogene · doi:10.1038/onc.2011.266 · Cited by 168
Alterations in VHL as potential biomarkers in renal-cell carcinoma
Gossage, L., & Eisen, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.42 · Cited by 167
Self-citationEsteban, M. A., Harten, S. K., Tran, M. G., & Maxwell, P. H. (2006) · Journal of the American Society of Nephrology · doi:10.1681/asn.2006020181 · Cited by 161
VHL loss causes spindle misorientation and chromosome instability
Thoma, C. R., Toso, A., Gutbrodt, K. L., Huber‐Reggi, S. P., Frew, I. J., Schraml, P., Hergovich, A., Moch, H., Meraldi, P., & Krek, W. (2009) · Nature Cell Biology · doi:10.1038/ncb1912 · Cited by 159
Hypoxia-inducible factor-2 regulates vascular tumorigenesis in mice
Rankin, E. B., Rha, J., Unger, T. L., Wu, C.-H., Shutt, H. P., Johnson, R. S., Simon, M., Keith, B., & Haase, V. H. (2008) · Oncogene · doi:10.1038/onc.2008.160 · Cited by 159
The von Hippel–Lindau Chuvash mutation promotes pulmonary hypertension and fibrosis in mice
Hickey, M. M., Richardson, T., Wang, T., Mosqueira, M., Arguiri, E., Yu, H. D., Yu, Q., Solomides, C., Morrisey, E. E., Khurana, T. S., et al. (2010) · Journal of Clinical Investigation · doi:10.1172/jci36362 · Cited by 153
Bommi‐Reddy, A., Almeciga, I., Sawyer, J., Geisen, C., Li, W., Harlow, E., Kaelin, W. G., & Grueneberg, D. A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806574105 · Cited by 151
Rankin, E. B., Higgins, D. F., Walisser, J. A., Johnson, R. S., Bradfield, C. A., & Haase, V. H. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.8.3163-3172.2005 · Cited by 150
Bishop, T., Lau, K. W., Epstein, A. C. R., Kim, S. K., Jiang, M., O’Rourke, D., Pugh, C. W., Gleadle, J., Taylor, M. S., Hodgkin, J., et al. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020289 · Cited by 149
Kishida, T., Stackhouse, T. M., Chen, F., Lerman, M. I., & Zbar, B. (1995) · PubMed · Cited by 148
Crossey, P. A., Foster, K., Richards, F. M., Phipps, M. E., Latif, F., Tory, K., Jones, M. H., Bentley, E., Kumar, R., Lerman, M., et al. (1994) · Human Genetics · doi:10.1007/bf00218913 · Cited by 148
Self-citationZatyka, M., da Silva, N. F., Clifford, S. C., Morris, M. R., Wiesener, M. S., Eckardt, K., Houlston, R. S., Richards, F. M., Latif, F., & Maher, E. R. (2002) · PubMed · doi:10.25405/ncl.34582002 · Cited by 147
Self-citationvan Rooijen, E., Voest, E. E., Logister, I., Korving, J., Schwerte, T., Schulte‐Merker, S., Giles, R. H., & van Eeden, F. J. (2009) · Blood · doi:10.1182/blood-2008-07-167890 · Cited by 146
Genetic Basis of Congenital Erythrocytosis: Mutation Update and Online Databases
Bento, C., Percy, M. J., Gardie, B., Maia, T. M., van Wijk, R., Perrotta, S., Ragione, F. D., Almeida, H., Rossi, C., Girodon, F., et al. (2013) · Human Mutation · doi:10.1002/humu.22448 · Cited by 144
Gallou‐Kabani, C., Joly, D., JEAN, A. M., Staroz, F., Martin, N., Tarlet, G., Orfanelli, M.-T., Bouvier, R., Droz, D., tien, Y. C., et al. (1999) · Human Mutation · doi:10.1002/(sici)1098-1004(1999)13:6<464::aid-humu6>3.0.co;2-a · Cited by 144
Software and database for the analysis of mutations in the VHL gene
Béroud, C. (1998) · Nucleic Acids Research · doi:10.1093/nar/26.1.256 · Cited by 143
Primary Cilium Formation Requires von Hippel-Lindau Gene Function in Renal-Derived Cells
Lutz, M. S., & Burk, R. D. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0501 · Cited by 141
Elongin BC complex prevents degradation of von Hippel-Lindau tumor suppressor gene products
Schoenfeld, A. R., Davidowitz, E. J., & Burk, R. D. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.15.8507 · Cited by 140
Jiang, Y., Zhang, W., Kondo, K., Klco, J. M., Martin, T. B. S., Dufault, M. R., Madden, S. F., Kaelin, W. G., & Nacht, M. (2003) · PubMed · Cited by 139
Blankenship, C., Naglich, J. G., Whaley, J. M., Seizinger, B. R., & Kley, N. (1999) · Oncogene · doi:10.1038/sj.onc.1202473 · Cited by 138
Gossage, L., Murtaza, M., Slatter, A. F., Lichtenstein, C. P., Warren, A. Y., Haynes, B., Marass, F., Roberts, I., Shanahan, S. J., Claas, A., et al. (2013) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22116 · Cited by 137
Self-citationMutations in the VHL gene in sporadic apparently congenital polycythemia
Pastore, Y. D., Jelinek, J., Ang, S., Guan, Y., Liu, E., Jedlickova, K., Krishnamurti, L., & Prchal, J. T. (2003) · Blood · doi:10.1182/blood-2002-06-1843 · Cited by 136
Mikhaylova, O., Ignacak, M. L., Barankiewicz, T. J., Harbaugh, S. V., Yi, Y., Maxwell, P. H., Schneider, M., Geyte, K. V., Carmeliet, P., Revelo, M. P., et al. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.01231-07 · Cited by 135
Silva, J. D., Lacombe, C., Bruneval, P., Casadevall, N., Leporrier, M., Camilleri, J.-P., Bariety, J., Tambourin, P. E., & Varet, B. R. (1990) · Blood · doi:10.1182/blood.v75.3.577.577 · Cited by 129
Treatment selection in metastatic renal cell carcinoma: expert consensus
Escudier, B. J., Szczylik, C. A., Porta, C., & Gore, M. E. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.59 · Cited by 128
Modulating Hypoxia-Inducible Transcription by Disrupting the HIF-1–DNA Interface
Nickols, N. G., Jacobs, C. S., Farkas, M. E., & Dervan, P. B. (2007) · ACS Chemical Biology · doi:10.1021/cb700110z · Cited by 128
VHL-mediated hypoxia regulation of cyclin D1 in renal carcinoma cells.
Bindra, R. S., Vasselli, J. R., Stearman, R. S., Linehan, W. M., & Klausner, R. D. (2002) · PubMed · Cited by 127
Kurban, G., Hudon, V., Duplan, E., Ohh, M., & Pause, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2560 · Cited by 126
Krieg, M., Marti, H. H., & Plate, K. H. (1998) · Blood · doi:10.1182/blood.v92.9.3388 · Cited by 126
Franke, G., Bausch, B., Hoffmann, M. M., Cybulla, M., Wilhelm, C., Kohlhase, J., Scherer, G., & Neumann, H. P. H. (2009) · Human Mutation · doi:10.1002/humu.20948 · Cited by 124
Influence of the RNA-Binding Protein HuR in pVHL-Regulated p53 Expression in Renal Carcinoma Cells
Galbán, S., Martindale, J. L., Mazan-Mamczarz, K., de Silanes, I. L., Fan, J., Wang, W., Decker, J., & Gorospe, M. (2003) · Molecular and Cellular Biology · doi:10.1128/mcb.23.20.7083-7095.2003 · Cited by 123
Baba, M., Hirai, S., Yamada‐Okabe, H., Hamada, K., Tabuchi, H., Kobayashi, K., Kondo, K., Yoshida, M., Yamashita, A., Kishida, T., et al. (2003) · Oncogene · doi:10.1038/sj.onc.1206373 · Cited by 122
Wang, L., Tsutsumi, S., Kawaguchi, T., Nagasaki, K., Tatsuno, K., Yamamoto, S., Sang, F., Sonoda, K., Sugawara, M., Saiura, A., et al. (2011) · Genome Research · doi:10.1101/gr.123109.111 · Cited by 122
Li, L., Zhang, L., Zhang, X., Yan, Q., Minamishima, Y. A., Olumi, A. F., Mao, M., Bartz, S. R., & Kaelin, W. G. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00282-07 · Cited by 120
Binding of Natively Unfolded HIF-1α ODD Domain to p53
Sánchez‐Puig, N., Veprintsev, D. B., & Fersht, A. R. (2005) · Molecular Cell · doi:10.1016/j.molcel.2004.11.019 · Cited by 117
Rechsteiner, M., von Teichman, A., Nowicka, A., Sulser, T., Schraml, P., & Moch, H. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0757 · Cited by 112
Rini, B. I., Jaeger, E., Weinberg, V. E., Sein, N., Chew, K., Fong, K., Simko, J., Small, E. J., & Waldman, F. M. (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2006.06376.x · Cited by 111
Hickey, M. M., Lam, J. C., Bezman, N. A., Rathmell, W. K., & Simon, M. C. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32614 · Cited by 110
Kurban, G., Duplan, E., Ramlal, N., Hudon, V., Sado, Y., Ninomiya, Y., & Pause, A. (2007) · Oncogene · doi:10.1038/sj.onc.1210709 · Cited by 109
Pantuck, A. J., An, J., Liu, H., & Rettig, M. B. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2211 · Cited by 108
Fu, L., Wang, G., Shevchuk, M. M., Nanus, D. M., & Gudas, L. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1745 · Cited by 102
Okuda, H., Hirai, S.-I., Takaki, Y., Kamada, M., Baba, M., Sakai, N., Kishida, T., Kaneko, S., Yao, M., Ohno, S., et al. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1347 · Cited by 100
Maranchie, J. K., Afonso, A. M., Albert, P. S., Kalyandrug, S., Phillips, J. L., Zhou, S., Peterson, J. C., Ghadimi, Β. M., Hurley, K., Riss, J., et al. (2003) · Human Mutation · doi:10.1002/humu.10302 · Cited by 98
Webster, A. R., Richards, F. M., MacRonald, F. E., Moore, A. T., & Maher, E. R. (1998) · The American Journal of Human Genetics · doi:10.1086/302037 · Cited by 98
Self-citationChoueiri, T. K., Fay, A. P., Gagnon, R., Lin, Y., Bahamón, B., Brown, V. E., Rosenberg, J. E., Hutson, T. E., Baker-Neblett, K. L., Carpenter, C. L., et al. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0491 · Cited by 97
Harten, S. K., Shukla, D., Barod, R., Hergovich, A., Balda, M. S., Matter, K., Esteban, M. A., & Maxwell, P. H. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e08-06-0566 · Cited by 95
Duns, G., Hofstra, R. M. W., Sietzema, J. G., Hollema, H., van Duivenbode, I., Kuik, A., Giezen, C., Osinga, J., de Boer-Bergsma, J. J., Bijnen, H., et al. (2012) · Human Mutation · doi:10.1002/humu.22090 · Cited by 90
pVHL Function Is Essential for Endothelial Extracellular Matrix Deposition
Tang, N., Mack, F. A., Haase, V. H., Simon, M. C., & Johnson, R. S. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2519-2530.2006 · Cited by 90
Hergovich, A., Lisztwan, J. H., Thoma, C. R., Wirbelauer, C., Barry, R. E., & Krek, W. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00232-06 · Cited by 89
Roberts, A. M., Watson, I. R., Evans, A. J., Foster, D. A., Irwin, M. S., & Ohh, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-1770 · Cited by 88
Genotype-phenotype correlation in von Hippel-Lindau families with renal lesions
Gallou‐Kabani, C., Chauveau, D., Richard, S., Joly, D., Giraud, S., Olschwang, S., Martin, N., Saquet, C., Chrétien, Y., Méjean, A., et al. (2004) · Human Mutation · doi:10.1002/humu.20082 · Cited by 86
Russell, R. C., Sufan, R. I., Zhou, B. R., Heir, P., Bunda, S., Sybingco, S. S., Greer, S. N., Roche, O., Heathcote, S. A., Chow, V. W. K., et al. (2011) · Nature Medicine · doi:10.1038/nm.2370 · Cited by 83
Knauth, K., Bex, C., Jemth, P., & Buchberger, A. (2005) · Oncogene · doi:10.1038/sj.onc.1209062 · Cited by 83
Esteban-Barragán, M. A., Ávila, P., Álvarez-Tejado, M., Gutiérrez, M. D. C., García-Pardo, A., Sánchez‐Madrid, F., & Landázuri, M. O. (2002) · PubMed · Cited by 83
Gläsker, S. (2001) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp.70.5.644 · Cited by 82
Interaction of Hydroxylated Collagen IV with the von Hippel-Lindau Tumor Suppressor
Grosfeld, A., Stolze, I. P., Cockman, M. E., Pugh, C. W., Edelmann, M. J., Kessler, B. M., Bullock, A. N., Ratcliffe, P. J., & Masson, N. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m611648200 · Cited by 81
Somatic VHL alteration and its impact on prognosis in patients with clear cell renal cell carcinoma
Kim, J. H., Jung, C., Cho, Y., Lee, J., Lee, S., Kim, H., Park, J., Park, J.-O., Kım, K., Kim, W. B., et al. (2005) · Oncology Reports · doi:10.3892/or.13.5.859 · Cited by 80
Genotype–phenotype correlations in VHL exon deletions
McNeill, A., Rattenberry, E., Barber, R. M., Killick, P., MacDonald, F., & Maher, E. R. (2009) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.33023 · Cited by 79
Self-citationEmerging Roles of microRNAs in the Molecular Responses to Hypoxia
Crosby, M. E., Devlin, C. M., Glazer, P. M., Calin, G. A., & Ivan, M. (2009) · Current Pharmaceutical Design · doi:10.2174/138161209789649367 · Cited by 77
García-Donás, J., Leandro-Garcia, L. J., del Alba, A. G., Morente, M. M., Alemany, I., Esteban, E., Arranz, J. Á., Climent, M. A., Gallardo, E., Castellano, D., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt219 · Cited by 75
Von Hippel-Lindau disease in a Newfoundland kindred.
Green, J. S., Bowmer, M. I., & Johnson, G. J. (1986) · PubMed · Cited by 74
Molecular Pathways in Renal Cell Carcinoma—Rationale for Targeted Treatment
KIM, W., & KAELINJR, W. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.06.001 · Cited by 73
An, J., Fisher, M., & Rettig, M. B. (2004) · Oncogene · doi:10.1038/sj.onc.1208348 · Cited by 69
Quantitative image analysis identifies pVHL as a key regulator of microtubule dynamic instability
Thoma, C. R., Matov, A., Gutbrodt, K. L., Hoerner, C. R., Smole, Z., Krek, W., & Danuser, G. M. (2010) · The Journal of Cell Biology · doi:10.1083/jcb.201006059 · Cited by 67
Fibronectin is a hypoxia‐independent target of the tumor suppressor VHL
Bluyssen, H. A. R., Lolkema, M. P., van Beest, M., Boone, M., Snijckers, C. M. J. T., Los, M., Gebbink, M. F. B. G., Braam, B. G., Holstege, F. C. P., Giles, R. H., et al. (2003) · FEBS Letters · doi:10.1016/s0014-5793(03)01392-9 · Cited by 60
Rechsteiner, M., von Teichman, A., Nowicka, A., Sulser, T., Schraml, P., & Moch, H. (2011) · Zurich Open Repository and Archive (University of Zurich) · doi:10.5167/uzh-48869 · Cited by 59
An Important von Hippel-Lindau Tumor Suppressor Domain Mediates Sp1-Binding and Self-Association
Cohen, H. T., Zhou, M., Welsh, A. M., Zarghamee, S., Scholz, H., Mukhopadhyay, D., Kishida, T., Zbar, B., Knebelmann, B., & Sukhatme, V. P. (1999) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1999.1767 · Cited by 57
Bento, C., Almeida, H., Maia, T. M., Relvas, L., Oliveira, A. C., Rossi, C., Girodon, F., Fernández-Lago, C., Aguado‐Diaz, A., Fraga, C., et al. (2013) · European Journal Of Haematology · doi:10.1111/ejh.12170 · Cited by 53
Fu, L., Wang, G., Shevchuk, M. M., Nanus, D. M., & Gudas, L. J. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3983 · Cited by 52
Frequent Overexpression of Vascular Endothelial Growth Factor Gene in Human Renal Cell Carcinoma.
Sato, K., Terada, K., Sugiyama, T., et al. (1994) · The Tohoku Journal of Experimental Medicine · doi:10.1620/tjem.173.355 · Cited by 49
Datta, K., Mondal, S., Sinha, S., Li, J., Wang, E., Knebelmann, B., Karumanchi, S. A., & Mukhopadhyay, D. (2005) · Oncogene · doi:10.1038/sj.onc.1208912 · Cited by 49
Lanikova, L., Lorenzo, F., Yang, C., Vankayalapati, H., Drachtman, R. A., Divoký, V., & Prchal, J. T. (2013) · Blood · doi:10.1182/blood-2012-11-469296 · Cited by 48
Cascón, A., Escobar, B., Montero‐Conde, C., Rodríguez‐Antona, C., Ruiz‐Llorente, S., Osório, A., Mercadillo, F., Letón, R., de Campos, J. M., García‐Sagredo, J. M., et al. (2007) · Human Mutation · doi:10.1002/humu.20496 · Cited by 46
Tomašić, N., Piterkova, L., Huff, C., Bilić, E., Yoon, D., Miasnikova, G., Sergueeva, A., Niu, X., Nekhai, S. A., Gordeuk, V. R., et al. (2013) · Haematologica · doi:10.3324/haematol.2012.070508 · Cited by 46
Welford, S. M., Dorie, M. J., Li, X., Haase, V. H., & Giaccia, A. J. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01618-09 · Cited by 44
Ricketts, C. J., Zeegers, M. P., Lubiński, J., & Maher, E. R. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006037 · Cited by 43
Self-citationAn, W. G., Chuman, Y., Fojo, T., & Blagosklonny, M. V. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4193 · Cited by 42
Petrella, B. L., & Brinckerhoff, C. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-66 · Cited by 42
Danilin, S., Sourbier, C., Thomas, L., Rothhut, S., Lindner, V., Helwig, J., Didier Jacqmin, D., Lang, H., & Massfelder, T. (2008) · Carcinogenesis · doi:10.1093/carcin/bgn275 · Cited by 38
Genetic and Pharmacological Strategies to Refunctionalize the von Hippel Lindau R167Q Mutant Protein
Ding, Z., Germán, P., Bai, S., Reddy, A. S., Liu, X.-D., Sun, M., Zhou, L., Chen, X., Zhao, X., Wu, C., et al. (2014) · Cancer Research · doi:10.1158/0008-5472.can-13-3213 · Cited by 31
Viger, A., & Dervan, P. B. (2006) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2006.08.028 · Cited by 28
Woldemichael, G. M., Vasselli, J. R., Gardella, R. S., McKee, T. C., Linehan, W. M., & McMahon, J. B. (2006) · SLAS DISCOVERY · doi:10.1177/1087057106289234 · Cited by 27
Cited by
Capitanio, U., & Montorsi, F. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00046-x · Cited by 1,014
Targeting the HIF2–VEGF axis in renal cell carcinoma
Choueiri, T. K., & Kaelin, W. G. (2020) · Nature Medicine · doi:10.1038/s41591-020-1093-z · Cited by 477
Ubiquitin ligases in oncogenic transformation and cancer therapy
Senft, D., Qi, J., & Ronai, Z. A. (2018) · Nature Reviews Cancer · doi:10.1038/nrc.2017.105 · Cited by 489
The ever-expanding role of HIF in tumour and stromal biology
LaGory, E. L., & Giaccia, A. J. (2016) · Nature Cell Biology · doi:10.1038/ncb3330 · Cited by 430
Miess, H., Dankworth, B., Gouw, A. M., Rosenfeldt, M., Schmitz, W., Jiang, M., Saunders, B., Howell, M., Downward, J., Felsher, D. W., et al. (2018) · Oncogene · doi:10.1038/s41388-018-0315-z · Cited by 361
Metadata
- Authors
- Gossage, L., Eisen, T., & Maher, E. R.
- Venue
- Nature Reviews Cancer
- Published
- 2014-12-23
- Volume
- 15
- Issue
- 1
- Pages
- 55-64
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2068919366
- Cited by
- 774
- References
- 205
- FWCI
- 8.87
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.